Bausch Health Companies (BHC) Operating Margin (2009 - 2026)
Bausch Health Companies (BHC) reported Operating Margin of 37.64% for Q1 2026, down 4986.0% on a YoY basis from 0.77% in Q1 2025, and down 322.02% sequentially from 16.95% in Q4 2025.
Bausch Health Companies (BHC) Operating Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Operating Margin data on file, last reported at 37.64% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 4986.0% year-over-year to 37.64%; the trailing twelve-month figure through Mar 2026 stood at 5.57% (down 1026.0% YoY), and the FY2025 full-year result was 17.66%, up 160.0% from the prior year.
- Operating Margin declined to 37.64% in Q1 2026, from 16.95% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 23.09% in Q3 2025 to a low of 37.64% in Q1 2026.
- A 5-year average of 9.63% and a median of 13.05% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin jumped 2579 bps in 2023 and slumped 4986 bps in 2026, its largest moves.
- Tracing BHC's Operating Margin over 5 years: stood at 10.76% in 2022, then soared by 240 bps to 15.03% in 2023, then surged by 45 bps to 21.81% in 2024, then declined by 22 bps to 16.95% in 2025, then sank by 322 bps to 37.64% in 2026.
- Business Quant data shows BHC's Operating Margin at 37.64% in Q1 2026, 16.95% in Q4 2025, and 23.09% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | -37.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.64% |
| Dec 31, 2025 | 16.95% |
| Sep 30, 2025 | 23.09% |
| Jun 30, 2025 | 17.55% |
| Mar 31, 2025 | 12.22% |
| Dec 31, 2024 | 21.81% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 16.19% |
| Mar 31, 2024 | 13.05% |
| Dec 31, 2023 | 15.03% |
| Sep 30, 2023 | 0.63% |
| Jun 30, 2023 | 19.01% |
| Mar 31, 2023 | 9.00% |
| Dec 31, 2022 | -10.76% |
| Sep 30, 2022 | 11.93% |
| Jun 30, 2022 | 8.19% |
| Mar 31, 2022 | 14.86% |
| Dec 31, 2021 | 5.07% |
| Sep 30, 2021 | 27.19% |
| Jun 30, 2021 | -12.86% |